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Background. Pathological accumulation of cholesterol in late endosomes is observed in lysosomal storage diseases such as
Niemann-Pick type C. We here analyzed the effects of cholesterol accumulation in NPC cells, or as phenocopied by the drug
U18666A, on late endosomes membrane organization and dynamics. Methodology/Principal Findings. Cholesterol
accumulation did not lead to an increase in the raft to non-raft membrane ratio as anticipated. Strikingly, we observed a 2–
3 fold increase in the size of the compartment. Most importantly, properties and dynamics of late endosomal intralumenal
vesicles were altered as revealed by reduced late endosomal vacuolation induced by the mutant pore-forming toxin ASSP,
reduced intoxication by the anthrax lethal toxin and inhibition of infection by the Vesicular Stomatitis Virus. Conclusions/
Significance. These results suggest that back fusion of intralumenal vesicles with the limiting membrane of late endosomes is
dramatically perturbed upon cholesterol accumulation.
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Trafficking. PLoS ONE 2(9): e851. doi:10.1371/journal.pone.0000851
INTRODUCTION
Mammalian cells harbor a complex endocytic pathway that fulfills
a variety of functions such as uptake of nutrients, recycling of
proteins and lipids back to the plasma membrane, down-
regulation of signaling receptors, detection and destruction of
pathogens [1,2,3]. Endosomes also extensively communicate with
the biosynthetic pathway, both in an anterograde and a retrograde
manner. In order to ensure proper targeting of proteins and lipids
to the correct destination in the cell, sorting occurs at three stages
of the pathway: the plasma membrane, the early endosomes and
the late endosomes. Of these compartments, the late endosome
appears to be the most complex in terms of morphology [4].
Sorting in late endosomes determines whether proteins or lipids
are targeted for degradation in lysosomes, recycled to the
endoplasmic reticulum or the Golgi apparatus [5], or, in specific
cell types, transported to the plasma membrane [6] or secreted
into the extracellular medium through the exosomal pathway [7].
Late endosomes contain tubular and cisternal regions, the later
being moreover multivesicular or multilamelar. In addition, late
endosomes, as early endosomes, are thought to be composed of
a mosaic of domains [1,8] that are determined by protein-protein,
protein-lipid and lipid-lipid interactions. In particular, platforms
organized by the small GTPases Rab7 and Rab9 have been
observed [9]. In addition to this compartmentalization of the
limiting membrane of the organelle–which is in contact with the
cytoplasm–compartmentalization between the limiting membrane
and the intralumenal membranes occurs [10]. Proteins such as the
lysosomal glycoprotein Lamp1 is almost exclusively found on the
limiting membrane while others such as the mannose-6-phosphate
receptor are abundant in intralumenal vesicles. Lipid segregation
also occurs as illustrated by the strong accumulation of the
unconventionnal lipid lysobisphosphatidic acid (LBPA) on internal
membranes. We have also recently shown that late endosomes
contain lipid raft-like domains both on their limiting and internal
membranes, but that the protein composition and physical
chemical properties of these domains are different [11].
A heterogeneous class of diseases united under the name of lipid
storage diseases leads to the pathological accumulation of specific
lipids in late endosomes, which are subsequently thought to trigger
membrane trafficking defects [12,13]. The consequences of the
accumulation of a given lipid on membrane organization,
compartmentalization and function are still poorly understood.
We were here interested in the consequences of late endosomal
cholesterol accumulation as encountered in the Niemann Pick
Type C disease (NPC) [13]. NPC is a fatal, autosomal recessive
neurodegenerative disease due to mutations in the NPC1 or NPC2
genes [14]. The main biochemical manifestation in NPC is
elevated late endosomal accumulation of free cholesterol
[15,16,17] followed by an increase in sphingolipids [18]. It has
been proposed that endosomal accumulation of cholesterol and
sphingolipids would lead to an overload of cholesterol rich raft-like
membrane domains (i.e. an increase in raft to non raft membrane
ratio) and cause in a general jam in traffic through the
compartment [19].
Using morphological, chemical and functional approaches, we
have here analyzed the consequences of cholesterol accumulation
using either NPC1 cells or negatively charged amine 3beta-(2-
diethylaminoethoxy)-androstenone HCl (U18666A) [20], a drug
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which is well established to phenocopy mutations in the NPC1
gene. The exact targets of U18666A have not been identified and
thus the mechanisms by which the drug triggers late endosome/
lysosomes cholesterol accumulation remain obscure. We found
that cholesterol accumulation did not lead to raft overload as
anticipated. However stabilization of raft-like domains and
decreased trafficking between the intralumenal vesicles and the
limiting membrane of the compartment was observed associated
with a drastic enlargement of compartment.
RESULTS
Isolation of cholesterol-loaded late endosomes
To study the effect of late endosomal cholesterol accumulation at
the organellar level, we used the baby hamster kidney (BHK) cell
line for which a well-established subcellular fractionation protocol
is available [21,22]. The NPC phenotype was induced using the
drug U18666A [20,23,24]. As expected, treatment with 3 mg/ml
U18666A for 18 hours led to the accumulation of cholesterol,
detected using the fluorescent probe filipin, in late endosomes co-
localizing with the unconventional lipid LBPA [25] (Fig 1A).
Late endosomes from control and U18666A-treated cells were
then isolated. Fractionation properties were not significantly
altered by cholesterol accumulation, since the small GTPase
Rab7, a late endosomal marker [26], was recovered at the same
low density position on the gradient as in the untreated controls
(8%–25% sucrose interface) (Fig 1B). Also, U18666A did not lead
to an increased contamination by other membranes since, as for
control cells, the small GTPase rab5 (early endosomal marker),
calnexin (endoplasmic reticulum marker), caveolin-1 (caveolar
marker) and ß-galactosyl transferase (Golgi enzyme) could not be
detected in the fraction (Fig. 1B).
We then analyzed the cholesterol content of purified late
endosomes from control and U18666A treated cells by comparing
yields (Fig. 1C, equal volumes of the late endosomal fractions were
analyzed) and enrichment (Fig 1D, equal amounts of proteins from
the late endosomal fractions were analyzed). As expected, the late
endosomal fraction from U18666A treated cells contained
significantly (2.6 fold) more cholesterol than that of control cells
(Fig. 1C) in agreement with previous studies [27]. Surprisingly
however, this drug-induced increase in cholesterol was small (1.3
fold, Fig 1D), when normalized to the protein content. Indeed the
late endosomal fraction obtained from U18666A-treated cells
contained more protein than controls (Fig. 1E). This relatively
mild increase in cholesterol levels was also observed in late
endosomes from cells of NPC patients [28].
Cholesterol accumulation in late endosomes leads
to an increase in compartment size
The fact that both the amount of cholesterol and the amount of
protein increased in late endosomes of U18666A treated cells
suggested that either the size or the number of late endosomes had
increased. To address this issue, we compared the volume of late
endosomes in control and U18666A-treated cells, after quantifica-
tion by electron microscope using stereological methods. Late
endosomes of control and U18666A-treated BHK cells were labeled
by fluid phase uptake of horseradish peroxidase (HRP) for 60 min at
37uC followed by a 10 min chase. As shown in Fig. 2A, treatment
with U18666A led to larger endocytic structures. Some late
endosomes also contained large spherical lipid droplet-like structures
(Fig. 2A), which are also typically found in NPC cells [24]. After
stereological analysis of randomly sampled sections, the volume of
late endosomes/volume of cytoplasm was estimated to be 3.0560.72
in control cells vs. 6.8261.18 in U18666A-treated cells, i.e. a 2.2 fold
increase. Assuming no change in cell volume upon U18666A
treatment, these results are remarkably similar to the increases in
protein and cholesterol content of the late endosomal fraction. We
also analyzed the size of HRP-labeled profiles. As shown in Fig. 2B,
the distribution of sizes was significantly shifted to larger profiles
upon U18666A treatment, the mean diameter of late endosomes
being 5896219 nm (n=132) for control cells and 8506290 nm
(n=186) for U18666A treated cells.
These experiments thus show that U18666A-induced choles-
terol accumulation in late endosomes is accompanied by
a concomitant increase in the size of the compartment. We
wondered whether this was also the case for cholesterol
accumulation triggered by the expression of deficient NPC1
protein. To compare cells with the same genetic background, we
made use of the NPC1 deficient CHO cell line CT43, and its
parental line, 25RA [29]. We also compared fibroblasts from
NPC1 patients to that of control human fibroblasts [24]. Both for
CHO CT43 cells and NPC1 fibroblasts, the volume of late
endosomes/volume of cytoplasm was increased by 3 fold when
compared to their respective control (Fig. 3). Thus, whether late
endosomal cholesterol accumulation was triggered by U18666A or
mutations in the NPC1 protein, the size of late endosomes
increased 2 to 3 fold. These findings explain the earlier
observations that the intracellular accumulation of the lysosomo-
tropic compound methylamine is increased in NPC1 patients [30].
Effects of U18666A on the phospholipid
composition of late endosomes and their DRMs
We next analyzed the effect of U18666A on the phospholipid
composition of late endosomes. Lipids were extracted and the
relative proportions of phosphatidyl choline (PC), phosphatidyl
ethanolamine (PE), phosphatidyl inositol (PI), phosphatidyl serine
(PS), sphingomyelins (SM) and LBPA were analyzed by 2
dimensional thin layer chromatography [11,25]. Each spot on
the 2D TLC plate was quantified by densitometry and expressed
as a percentage of the total intensity on the plate. The overall
profile was very similar for late endosomes of control vs. drug
treated cells (Fig. 4A) with the notable exceptions of a 27%
decrease in sphingomyelin, in marked contrast to what has been
observed in NPC1 cells [28]. U18666A treated cells also showed
an inversion of the PC to PE ratio (1.75 in control vs. 0.69 in
U18666A). This change in ratio reflects the global increase in
cellular PE upon U18666A treatment leading also to an overall
inversion of the PC/PE ratio (Fig. 4B) (PC/PE ratio 1.41 in
control cells vs. 0.73 in U18666A treated cells).
We next investigated whether U18666A would affect the
composition/abundance of DRMs in late endosomes. The choles-
terol profile along the Optiprep gradient was remarkably similar for
late endosomes of U18666A treated and control cells, the low
buoyant fractions 1 and 2 containing some 40% of the total
cholesterol (Fig. 5A). We next analyzed the lipid composition of the
DRMs fractions (fractions 1+2, Fig. 5C) in comparison to that of the
detergent soluble fraction 6 (Fig. 5D). As previously observed for
DRM fractions from late endosomes of control cells [11], the three
major phospholipids in DRMs from late endosomes of U18666A
treated cells were SM, PC and PE. These DRMs also contained the
4 unknown lipids (termed I1 to I4) detected in the DRMs of late
endosomes from control cells [11]. Also the lipid composition of the
soluble fraction of late endosomes from U18666A treated cells were
remarkably similar to that observed for control cells (Fig. 5D). The
only notable exception was a slight decrease in SM content (16% vs.
22%) in the DRM fractions and an inversion of the PE/PC ratio as
also observed in Fig. 4 for the entire compartment.
Late Endosomal Cholesterol
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Effect of U18666A on the protein composition of
late endosomal domains
We next investigated the effect of U18666A on late endosomal
proteins. The total amounts of Lamp-1, Rab 7 and GPI-anchored
proteins (N-CAM120, semaphorin-7 and Thy-1) were increased
upon U18666A treatment, with the exception of flotillin, which
was slightly decreased (Fig. 6A lanes Yield: the same proportion of
each late endosomal fraction was analyzed, and Fig. 6B).
Therefore, with the exception of flotillin-1, the behavior of these
proteins paralleled that of the total late endosomal protein
population depicted in Fig. 1E. When equal amounts of LE
endosomal proteins were compared (Lanes labeled Enrichment,
10 mg of protein per lane), the relative amounts of lamp1 (although
not statistically significant) and Rab7 were increased upon
U18666A treated (Fig. 6A and 6C). Amounts of both flotillin-1
Figure 1. Purification of late endosomes from control and U18666A treated-BHK cells. BHK cells were treated or not with U18666A at 3 mg/ml for
18 hours. A: Cells were labeled with filipin (to detect cholesterol) and anti-LBPA antibodies. B: Cells were submitted to subcellular fractionation, as
described in experimental procedures, to separate late from early endosomes. 10 mg of protein from each fraction were separated in 12.5% SDS-PAGE
and blotted for the presence of the small GTPases rab7 (late endosomal marker) and rab5 (early endosomal marker), calnexin (endoplasmic reticulum
marker), caveolin-1 (caveolar marker) and ß-galactosyl transferase (Golgi enzyme). An equivalent proportion (C) or an equal amount of protein (D) of
the late endosomal fraction from BHK cells treated or not with U18666A (3 mg/ml for 18 hours) was submitted to lipid extraction and 1D TLC for
cholesterol determination. The cholesterol was quantified by densitometry. Error bars represent the standard deviation (n = 3). E: The protein content
of equivalent volume of the late endosomal fraction from BHK cells treated or not with U18666A was determined. Error bars represent the standard
deviation (n = 3).
doi:10.1371/journal.pone.0000851.g001
Late Endosomal Cholesterol
PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e851
and GPI-anchored proteins, however, were diminished (Fig. 6A
and 6C).
When analyzing the overall protein profile on Optiprep gradients
after detergent solubilization of late endosomes, a decrease in
solubilized proteins was observed upon U18666A treatment with
a concomitant<2-fold increase in DRM-associated proteins
(Fig. 6D). This was apparently not due to an abnormal raft
association of previously non-raft proteins since both rab7 and lamp1
remained detergent soluble (Fig. 7A). A relative increase in the DRM
association of flotillin-1–despite the late endosomal flotillin-1 levels
(Fig. 6C)–and MLN64 was observed (fig. 7A), whereas the behavior
of GPI-anchored proteins was not significantly altered (fig. 7B
compared to [11]). We also analyzed the distribution of annexin II
since this protein, which can associate with membranes in
a cholesterol dependent manner [31], was shown to redistribute
from early to late endosomes upon U18666A treatment as well as in
NPC1 cells [32]. As predicted, annexin II was not detectable in
control late endosomes, but was abundant and fully detergent-
soluble in late endosomes from U18666A-treated cells (Fig. 7A).
These observations strongly indicate that the increase in protein in
late endosomal DRMs observed upon U18666A treatment is due to
a specific subset of proteins.
We next wondered whether, in addition to being able to recruit
more proteins, late endosomal DRMs from U18666A-treated cells
Figure 2. U18666A leads to an enlargement of late endosomes. A: Control and U18666A treated cells were analyzed by electron microscopy. B: The
diameters of 132 late endosomes from control cells and 189 from U18666A treated cells was measured and the % of profiles for different size ranges
were determined and plotted.
doi:10.1371/journal.pone.0000851.g002
Figure 3. NPC1 deficiency leads to the enlargement of late endosomes. The % of cytoplasmic volume occupied by late endosomes was determined
by quantitative electron microscopy on U18666A treated late endosomes, NPC1 deficient CHO cells and fibroblast from an NPC1 patient [24] in
comparison to their respective controls.
doi:10.1371/journal.pone.0000851.g003
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had altered properties such as being more resistant to detergent
extraction at 37uC instead of 4uC. Whereas this treatment led to
solubilization of GPI-anchored proteins in control cells [11], the
proportion of DRM associated GPI-anchored proteins was similar
at 4 and 37uC for late endosomes from U18666A treated cells
(Fig. 7BC). This effect of U18666A appeared to be specific to late
endosomal DRMs since GPI-anchored proteins from total cell
extracts (presumably reflecting the presence of plasma membrane
where the bulk of GPI-anchored proteins reside) of U18666A
treated cells were solubilized by Triton X-100 at 37uC (Fig 7BC).
U18666A affects intra-endosomal trafficking
The increased resistance to detergent solubilization of late
endosomal GPI-anchored proteins upon U18666A treatment
raised the possibility that the dynamics of GPI-domains in
intralumenal vesicles were altered—indeed, we have previously
shown that GPI-anchored proteins reside mostly in intralumenal
membranes [11]. To test this possibility, we analyzed the effects of
U18666A on three events that rely on the dynamics of
intralumenal late endosomal membranes. We studied the effects
of the drug on two bacterial toxins that rely on lipid rafts for
intoxication and interact with late endosomes at crucial steps of
their mode of action–the mutant bacterial pore-forming toxin
ASSP [22] and the anthrax toxin [33,34]–, as well as one virus, the
Vesicular Stomatitis Virus (VSV) that relies on late endosomal
intralumenal vesicles for delivery of the nucleocapsid into the
cytoplasm [35].
ASSP is a mutant of aerolysin that retains its capacity to bind
specifically to GPI-anchored proteins but requires GPI-dependent
transport to late endosomes to form channels. It indeed contains
an engineered disulfide bridge that becomes reduced in late
endosomes, allow the toxin to heptamerize and form channels.
Channel formation, in the intralumenal vesicles as inferred by the
localization of GPI-anchored proteins [11], leads to vacuolation of
late endosomes [22] presumably by triggering back fusion of
intralumenal vesicles with the limiting membrane. Whereas ASSP
led to the appearance of cytoplasmic vacuoles in control cells,
U18666A treated cells retained their normal, unvacuolated
appearance (Fig. 8A and B). The lack of observed vacuolation
was not due to impaired transport from early to late endosomes in
U18666A treated cells since the toxin was equally reduced and
heptamerized in control and U18666A treated cells (Fig. 8C).
ASSP was still delivered to the intralumenal vesicles of late
endosomes as suggested by the fact that internalized Alexa-labeled
ASSP could be detected in punctate structures sometimes
surrounded by a ring of flotillin-1 (Fig. 8D).
The anthrax lethal toxin [36] also enters cells via a raft
dependent route [33] and remains associated with DRMs
throughout the endocytic pathway (Abrami and van der Goot,
unpublished observations). At the level of early endosomes, the
channel forming subunit of the toxin, the protective antigen (PA),
forms a channel in intralumenal vesicles and translocates, into
the lumen of these vesicles, its enzymatic subunit, called lethal
factor (LF) [34]. In order to get access to the cytoplasm, LF must
then be transported to late endosomes and await back fusion of
the intralumenal vesicles with the limiting membrane. To probe
for alteration in DRM containing intralumenal vesicle dynamics,
we investigated whether U18666A treatment would affect the
release of LF into the cytoplasm by monitoring the processing of
one of its targets, the MAP kinase kinase MEK1. As shown in
Fig. 9A, U18666A protected cells from anthrax lethal toxin
induced cleavage of MEK1. This was not due to altered
internalization of the toxin since the formation of the PA
channel, which forms in early endosomes, was unaltered by the
drug, as monitored by the appearance of an SDS-resistant
heptamer (Fig. 9A).
Finally, to further investigate the consequences of late
endosomal cholesterol overload, we made use of Vesicular
Stomatitis Virus (VSV), which infects cells from endosomes. The
acidic endosomal pH triggers fusion of the viral envelope with
endosomal membranes, thereby releasing the viral nucleocapsid
into the cytoplasm and allowing infection to proceed. Le Blanc et
al. [35] have recently shown that viral envelope fusion occurs
preferentially with the membrane of intralumenal vesicles, and not
with the limiting membrane, so that viral capsids remain hidden
Figure 4. Lipid composition of late endosomes from control and
U18666A treated cells. A: Late endosomes were purified from control
and U18666A treated cells. An equivalent amount of protein (100 mg)
from each late endosomal fraction was submitted to lipid extraction.
The samples were run on two dimensional thin layer chromatography
(TLC) plates for phospholipids analysis. The phospholipids were
quantified by densitometry and each one expressed as percentage of
the total amount of phospholipids on the plate. Error bars represent the
standard deviation (n = 3). I: unidentified lipid, PI: phosphatidyl inositol,
PS: phosphatidyl serine, PE: phosphatidyl ethanolamine, PC: phospha-
tidyl choline, LBPA: Lysobisphosphatidic acid. B: The content in total PC
and PE, corresponding to an equivalent amount of protein was
compared between control and U18666A treated cells.
doi:10.1371/journal.pone.0000851.g004
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within the lumen of these vesicles. Back fusion, as for the anthrax
toxin, allows release of the nucleocapsid to the cytoplasm and
infection of the cells. To monitor viral fusion events, we used an
established viral fusion assay [35]. Virions were labeled with self-
quenching amounts of Dil, a fluorescent long-chain dialkylcarbo-
cyanine dye, and bound to the cell surface at 4uC. After
endocytosis at 37uC, the fusion of individual virions was revealed
in the light microscope by the appearance of fluorescent spots in
endosomes, due to Dil de-quenching. Treatment with U18666A
had no effect on viral fusion, demonstrating that the drug did
not affect transport of viral particles to acidic endosomes, or
the low pH-mediated viral fusion itself. By contrast, VSV infection
was significantly reduced, presumably because capsids that
were released upon fusion then remained trapped within late
endosomes.
DISCUSSION
Late endosomes are arguably the most complex station of the
endocytic pathway due to their ability to communicate with other
organelles, i.e. inter organellar trafficking (with Golgi, lysosomes,
ER), but also due to the communication between the intralumenal
vesicles and the limiting membrane, i.e. intra organellar trafficking
[5]. Both proteins and lipids are responsible for generating and
maintaining the compartmentalization within this compartment
and its proper functioning. Our interest was to investigate the
effects of late endosomal cholesterol accumulation as observed in
cells from NPC patients.
Cholesterol accumulation was induced in BHK cells to allow
isolation of late endosomes by subcellular fractionation. Lipid
analysis revealed that the composition of late endosomes was
remarkably similar in control and U18666A treated cells with the
Figure 5. Lipid analysis of late endosomal DRMs from U18666A treated cells. DRMs were prepared from late endosomes (BHK cells +/2 U18666A)
by flotation on an OptiPrep gradient. Six fractions of 400 ml were collected. A: Lipids were extracted and the amount of cholesterol determined by 1D
TLC. Cholesterol contents were expressed as a percentage of the total cholesterol on the gradient. Error bars represent the standard deviation (n = 3).
B: After pooling fractions 1 and 2 from the top of the Optiprep gradient (corresponding to the DRMs), lipids were extracted and analyzed by 2D TLC
(shown TLC corresponds to the U18666A condition). I: unidentified lipid, PI: phosphatidyl inositol, PS: phosphatidyl serine, SM: sphingomyelins, PE:
phosphatidyl ethanolamine, PC: phosphatidyl choline, LBPA: Lysobisphosphatidic acid. C–D: The amount of each phospholipid in fractions 1+2 (C)
and fraction 6 (D) were quantified by densitometry. Each phospholipid is expressed as percentage of the total amount of phospholipids on the TLC
plate. Error bars represent the standard deviation (n = 3). E: In order to evaluate the distribution of SM, PS, PC, LBPA and I4 through out the Optiprep
gradient upon fractionation of late endosomes form U18666A treated cells, the content of these lipids in fractions 1+2 and in fraction 5+6 was
determined. For each lipid, the distribution between these two pools was plotted.
doi:10.1371/journal.pone.0000851.g005
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exception of a decrease in the percentage of sphingomyelin and an
inversion in the PC to PE ratio. Also the fraction of detergent
resistant cholesterol was unaltered suggesting that there was in fact
no change in the raft to non-raft ratio. The overall amount of
cholesterol was however increased as expected from the literature,
but it was accompanied by an almost compensating increase in the
amount of other lipids and of proteins. Quantitative electron
microscopy confirmed that the late endosomal compartment was
enlarged in U18666A treated cells. This was due to the cholesterol
accumulation and not to some side effect of the drug since a three-
fold increase in cytoplasmic volume occupied by late endosomes
was also observed in a CHO cell line deficient in NPC1 and in
fibroblast from an NPC1 patient.
The increase in late endosomal cholesterol however clearly did
not just lead to an identical, albeit larger, compartment, as most
drastically illustrated by the severity of the NPC phenotype [14].
Our analysis revealed significant difference that could contribute
to explain the altered properties of cholesterol laden late
endosomes. Although the increase in cholesterol was accompanied
by an increase in other organellar components, the compensatory
effect was not complete leading to a 30% increase in the
cholesterol to protein ratio in late endosomes upon U18666A
treatment. Also, although the proportion of DRMs was not altered
in U18666A treated cells, these became more resistant to
detergent solubilization possibly due to the increase in phospha-
tidyl ethanolamine. This lipid, due to its small head group, has
a significantly higher melting temperature than other phospholi-
pids [37] and thus promotes the formation of liquid ordered
domains. In addition, late endosomal DRMs from U18666A
treated cells showed a 2-fold increase in protein content suggesting
that protein dynamics within the membranes were altered.
Previous studies have established that late endosomal motility is
impaired in NPC and U18666A-treated [38,39,40] presumably
via an inhibition of the membrane-cytosol cycle of the small
GTPase Rab7, hence that inter organellar trafficking is reduced.
We now observe that intra-organellar traffic is also reduced, and
that dynamics of internal membranes were altered, as revealed by
the (1) reduced late endosomal vacuolation induced by the mutant
pore-forming toxin ASSP, (2) reduced intoxication by the anthrax
lethal toxin and (3) reduced infection by Vesicular Stomatitis
Virus, three events that are thought to rely on back fusion of
intralumenal vesicles with the limiting membrane of late endo-
somes [22,34,35]. Such inhibition of back fusion events in
U18666A-treated cells and NPC cells is expected to interfere
severely with the sorting and trafficking of proteins that cycle
between intraluminal and limiting membranes, as was shown for
Figure 6. Effect of U18666A on late endosomal proteins. A: Late endosomes were isolated from control and U18666A treated BHK cells. Fractions
were analyzed by SDS-PAGE either in terms of equal volume (Yield, same fraction of total late endosomes) or equal amount of protein (enrichment)
and immunoblotted for the presence of Lamp-1, Rab7, flotillin-1 (Flot-1) or GPI-anchored proteins, which were revealed using an aerolysin overlay.
BC: For each of these proteins, the change in abundance upon U18666A treatment vs. control was determined through quantitation by densitometry.
Quantifications were performed both for analysis by Yield and by Enrichment. Error bars represent the standard deviation (n = 3). * represent
statistically significant differences (p,0.05). D: DRMs were prepared from late endosomes (BHK cells +/2 U18666A) by flotation on an OptiPrep
gradient. Six 400 ml fractions were collected and their protein content determined. Each fraction protein content is expressed as percentage of the
total amount of proteins along the gradient. Error bars represent the standard deviation (n = 3).
doi:10.1371/journal.pone.0000851.g006
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the mannose-6-phosphate receptor [24]–a situation that may well
contribute to the complex pathology of NPC, and presumably of
other lipidosis that are accompanied by cholesterol accumulation
in late endocytic organelles [15].
Conclusion
Pathological increases in late endosomal cholesterol, such as
observed in NPC patients, led to a drastic enlargement of the
compartment and alteration of its properties. Unexpectedly however,
the raft to non-raft membrane ratio was not altered in late endosomes
of U18666A treated cells. But, the action of toxins and viruses that
target late endosome intralumenal membranes was significantly
reduced, supporting the notion that cholesterol accumulation inhibits
intra-endosomal membrane dynamics. Such perturbations of late
endosomal membrane domains, in particular raft-like membranes,
provide a reasonable explanation for altered protein and lipid
trafficking through the compartment in cholesterol storage diseases.
Figure 7. U18666A alters the detergent solubility of GPI-anchored proteins in late endosomes. A: DRMs were prepared from late endosomes (BHK
cells +/2 U18666A) by flotation on an OptiPrep gradient. Six fractions were collected from the top and analyzed by immunoblotting for the presence
of flotillin-1 (Flot-1), Rab7, Lamp-1, annexin II (AnnII) and MLN64. B: BHK cells treated or not with U18666A. Total cells or purified late endosomes were
solubilized in 1% Triton6100 at 4uC (as in A and all other figures) or 37uC. The lysats were submitted to flotation on Optiprep gradients, 6 fractions
collected and analyzed for the distribution of GPI-anchored proteins by aerolysin overlay. C: For the 4 conditions illustrated in B and for 3
independent experiments, the total GPI content of each fraction was quantified by densitometry and normalized to the total GPI-content of the
gradient. Error bars represent the standard deviation (n = 3). * represent statistically significant differences (p,0.05).
doi:10.1371/journal.pone.0000851.g007
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MATERIALS AND METHODS
Cell culture and drug treatment
Monolayer of baby hamster kidney (BHK) and Chinese Hamster
Ovary (CHO) [41,42,43]. For 3beta-(2-diethylaminoethoxy)-
androstenone HCl (U18666A) treatment, the cell culture medium
was removed 4 hours later after plating and fresh medium
containing U18666A at 3 mg/ml was added for 18 hours.
Subcellular fractionation
Late endosomal fraction was prepared as described [21,22].
Briefly, BHK cells were homogenized, a post-nuclear supernatant
was prepared and adjusted to 40.6% sucrose, 3 mM imidazole,
pH 7.4, loaded at the bottom of an SW41 tube, and overlaid
sequentially with 35 and 25% sucrose solutions in 3 mM
imidazole, pH 7.4, and then homogenization buffer (HB; 8.5%
sucrose, 3 mM imidazole, pH 7.4). The gradient was centrifuged for
90 min at 35 000 rpm. Early and late endosomal fractions were
collected at the 35/25% and 25%/HB interfaces respectively.
Isolation of DRMs from late endosomal fractions
DRMs were prepared from late endosomes as described by [22].
Briefly late endosomes were diluted four times, sedimented by
centrifugation (TLS.55 Beckman rotor, 30 min, 55 000 r.p.m.)
and resuspended in 200 ml of lysis buffer (25 mM Tris-HCl
pH 7.4, 150 mM NaCl, 5 mM EDTA) in the presence of
Complete, a cocktail of protease inhibitors (Roche) and 1%
Triton X-100. After 20 min of incubation at 4uC, the lysat was
adjusted to 40% OptiPrep (Nycodenz), overlaid with a 30% and
0% OptiPrep cushions and centrifuged for 2h centrifugation at 55
000 rpm (4uC) using a TLS.55 rotor. Six fractions were collected
from the top and precipitated with 6% trichloroacetic acid in the
presence of sodium deoxycholate as a carrier. When indicated,
DRMs were prepared after samples solubilization in Triton X-100
by high-speed centrifugation for 30 min at 55’000 using a tabletop
ultracentrifuge.
Phospholipid and cholesterol analysis
Lipids of late endosomes and late endosomes fractions obtained
with OptiPrep gradient centrifugation were extracted in CHCl3/
MeOH and then separated by two-dimensional thin layer
chromatography (TLC) for phospholipids analysis [25,44]. The
first dimension was run with chloroform, methanol, 32%
ammonia (65:35:5, v/v) and the second with chloroform/
acetone/methanol/acetic acid/water (50:20:10:12.5:5), v/v).
Phospholipids were revealed by burning the TLC plate at 160uC
after immersion in 1.5 mM cupric acetate-8% H3PO4 solution.
For cholesterol analysis, lipids were extracted as above, analyzed
on a one-dimensional TLC in heptane/ethylether/acetic acid
(18:6:2, v/v) and stained with copper. Both cholesterol and
phospholipids were quantified by densitometry using the ScanA-
nalysis software.
Figure 8. U18666A treatment protects cells against the action of ASSP. AB: BHK cells were treated with or not with U18666A for 8 hrs, followed by
9 hrs treatment, still in the presence of the drug, with the mutant aerolysin toxin ASSP (500 ng/ml). B. For each conditions, the number of vacuolated
cells, out of a total of n = 240, was counted. C: BHK cells were treated with trypsin nicked ASSP (500 ng/ml) either for 1 h at 4uC or for 24 h at 37uC.
For cells treated at 4uC, 20 mg of total cell extracts were analyzed for the presence of monomeric and heptameric aerolysin by non-reducing SDS-
PAGE and Western blotting. Cells treated at 37uC, were submitted to subcellular fractionation to isolate late endosomes, which were analyzed for the
presence of monomeric and heptameric aerolysin by non-reducing SDS-PAGE and western blotting. Monomeric ASSP underwent differential
migration when reduced in late endosomes vs. non-reduced at the cell surface as previously observed [22]. D: BHK cells were treated with U18666A
for 8 hrs. Alexa-ASSP was subsequently added and allowed to be internalized for 6 hrs. Cells were fixed and processed for fluorescence microscopy to
detect flotillin-1 in late endosomes.
doi:10.1371/journal.pone.0000851.g008
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Immunoblotting, aerolysin overlays and protein
quantification
Proteins were separated by SDS-PAGE using 12.5% acrylamide
gels unless stated otherwise and transferred onto a nitrocellulose
membrane. Western blots were revealed with SuperSignal
Chemiluminescence (Pierce) and quantified by densitometry.
Aerolysin overlays were performed as described by [45]. Protein
contents of cellular fractions were determined using bicinchroninic
acid (BCA, Pierce).
Vesicular Stomatitis virus (VSV) infection and toxin
treatments
Before infection BHK cells grown on glass cover slips were treated
during 9 hours with U18666A. Cells were then incubated 1 h at
4uC with VSV (1 MOI) in MEM pH 7.4 followed by 3 h at 37uC,
in the presence of the drug. Finally cells were fixed and analyzed
by immunofluorescence and infection was quantified by counting
the number of cells expressing either newly synthesized VSV-G
protein or GFP [35]. Treatment of BHK cells with the mutant
pore-forming toxin ASSP and anthrax lethal toxin were performed
as described by [22,34] respectively.
Fluorescence Microscopy
Cells grown on cover slips were fixed with 3% paraformaldehyde
for 20 min at room temperature and saturated with 10%
phosphate-buffered saline-fetal calf serum (PBS-FCS) for 20 min.
Cholesterol was labeled with 50 mg/ml Filipin in 10% PBS-FCS.
For flotillin-1 labeling cell PFA fixed cells were permeabilized with
saponin and stained with a polyclonal antiflotillin-1 antibody [22].
Cells were mounted on microscopy slides. Images were acquired
using the IPLab Spectrum software (Scientific Image Processing).
Electron microscopy
BHK cells were treated with 3 mg/ml U18666A for 18 hours or
were incubated under identical conditions in the absence of the
drug. The cells were then incubated with HRP (10 mg/ml) for
60 min at 37uC followed by a further 10 min incubation without
HRP to allow the HRP to chase out of early endosomal
compartments. The cells were then fixed with 2.5% glutaralde-
hyde in PBS and processed for peroxidase detection and EM
embedding using standard conditions. Digital images of thin
sections were captured at random while scanning across the grid in
a regular unbiased manner. Images were overlaid with a lattice
grid generated in the imaging program (SIS SoftImaging Munster,
Germany). Volume of the HRP-containing compartments was
quantitated by point counting using double lattice grids to relate
points over HRP-labeled profiles to the cytoplasmic volume using
standard methods [46].
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